Myriad Genetics (NASDAQ:MYGN) and Dyadic International (NASDAQ:DYAI) Head to Head Analysis

Myriad Genetics (NASDAQ:MYGN) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Valuation and Earnings

This table compares Myriad Genetics and Dyadic International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50 million	0.38	-$365.90 million	($1.19)	-2.74
Dyadic International	$3.09 million	11.79	-$7.36 million	($0.23)	-4.35

Dyadic International has lower revenue, but higher earnings than Myriad Genetics. Dyadic International is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Myriad Genetics and Dyadic International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Analyst Ratings

This is a breakdown of current recommendations for Myriad Genetics and Dyadic International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2	3	1	0	1.83
Dyadic International	1	0	2	0	2.33

Myriad Genetics presently has a consensus target price of $5.38, indicating a potential upside of 64.88%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 200.00%. Given Dyadic International’s stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Myriad Genetics.

Insider & Institutional Ownership

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 27.9% of Dyadic International shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Myriad Genetics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.